Compare BioNTech SE - ADR (BNTX) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Freshworks Inc — how do they compare? BioNTech SE - ADR trades at $93.17 (market cap $23.31B), while Freshworks Inc trades at $11.64 (market cap $3.31B). The key difference: BioNTech SE - ADR is far larger — about 7× Freshworks Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | FRSH | |
|---|---|---|
Market Cap | $23.31B | $3.31B |
Sector | Health | Technology |
52-Week High | $119.34 | $13.97 |
52-Week Low | $83.89 | $6.88 |
Enterprise Value | $6.60B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Freshworks (FRSH) trades at $11.66, down 2.67% on the day, as the stock consolidates near key technical levels. The company demonstrates strong fundamental improvement with 16% revenue growth in Q2 2026 and achieving GAAP profitability for the first time this year. Recent positive developments include FedRAMP certification progress and Gartner leadership recognition, while analyst sentiment remains evenly split between Buy and Hold ratings with a $16.50 consensus price target representing significant upside potential.
The outlook appears favorable given Freshworks' transition to profitability, expanding AI capabilities, and strong EX business growth. Key risks include competitive pressures in the SaaS sector and the need to maintain recent momentum. With attractive valuation metrics and positive cash flow trends, the stock presents a compelling opportunity for investors seeking exposure to the growing service operations software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
